Kilambi News
Tuesday, November 17, 2026

Generate signs Zealand deal worth up to 1.2 billion dollars

Life Sciences Sunday, November 15, 2026 - Updated Nov 15, 2026 07:06

Generate Biomedicines disclosed a Zealand Pharma collaboration paying 30 million dollars upfront and up to nearly 1.2 billion dollars in total milestones, alongside third quarter results.

Why it matters: The deal is outside validation, and outside cash, for an AI designed protein platform whose lead asthma antibody is already in two Phase 3 studies.

Data as of Generate Biomedicines release of November 12, 2026, filed with the SEC and read in full from the filing. Quarter ended September 30, 2026. Filing accession 0001193125-26-456921. Milestone figures are potential totals, not received cash.

Generate Biomedicines reported third quarter results on November 12, in a release filed with the SEC that the previous edition did not cover, and the headline item is a collaboration with Denmark Zealand Pharma. The agreement pays Generate 30 million dollars upfront and 35 million dollars in early preclinical milestones, with total potential milestones of nearly 1.2 billion dollars plus tiered royalties. The release does not name the targets, and the milestone total is potential value over the life of the deal, not cash in hand.

The company also described a collaboration with Anthropic, building on AI agent guided CAR T research that produced smaller signalling domains with improved function in preclinical studies. Generate held 404.2 million dollars in cash, cash equivalents and marketable securities at September 30.

Its lead internal candidate, GB-0895, is an AI engineered anti TSLP antibody designed for dosing twice a year. Two global Phase 3 studies, SOLAIRIA-1 and SOLAIRIA-2, are running in severe uncontrolled asthma, testing 300 mg every 26 weeks against an annualised exacerbation rate over 52 weeks. Phase 1 and Phase 1b data showed a single dose sustaining inflammatory biomarker reductions for at least six months in asthma and in COPD, with a half life of about 98 days at the 300 mg dose.

In oncology, the company reported second cohort enrolment for GB-4362 in advanced urothelial cancer and first patient dosing of GB-5267 in platinum resistant ovarian cancer. The Zealand deal matters because it monetises the platform before any Generate product is approved, in the same week that Windward, another TSLP developer, reached the public market.

Sources

  1. Generate Biomedicines reports third quarter 2026 financial results and provides business update - Generate Biomedicines, via SEC Form 8-K Exhibit 99.1 - 2026-11-12